Correlation Between Transcode Therapeutics and Dermata Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Transcode Therapeutics and Dermata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Transcode Therapeutics and Dermata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Transcode Therapeutics and Dermata Therapeutics, you can compare the effects of market volatilities on Transcode Therapeutics and Dermata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Transcode Therapeutics with a short position of Dermata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Transcode Therapeutics and Dermata Therapeutics.

Diversification Opportunities for Transcode Therapeutics and Dermata Therapeutics

-0.25
  Correlation Coefficient

Very good diversification

The 3 months correlation between Transcode and Dermata is -0.25. Overlapping area represents the amount of risk that can be diversified away by holding Transcode Therapeutics and Dermata Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dermata Therapeutics and Transcode Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Transcode Therapeutics are associated (or correlated) with Dermata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dermata Therapeutics has no effect on the direction of Transcode Therapeutics i.e., Transcode Therapeutics and Dermata Therapeutics go up and down completely randomly.

Pair Corralation between Transcode Therapeutics and Dermata Therapeutics

Given the investment horizon of 90 days Transcode Therapeutics is expected to under-perform the Dermata Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Transcode Therapeutics is 1.14 times less risky than Dermata Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The Dermata Therapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  384.00  in Dermata Therapeutics on August 29, 2024 and sell it today you would lose (274.00) from holding Dermata Therapeutics or give up 71.35% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Transcode Therapeutics  vs.  Dermata Therapeutics

 Performance 
       Timeline  
Transcode Therapeutics 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Transcode Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Transcode Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Dermata Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Dermata Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Transcode Therapeutics and Dermata Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Transcode Therapeutics and Dermata Therapeutics

The main advantage of trading using opposite Transcode Therapeutics and Dermata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Transcode Therapeutics position performs unexpectedly, Dermata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will offset losses from the drop in Dermata Therapeutics' long position.
The idea behind Transcode Therapeutics and Dermata Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine